Koutaro Yokote

21.6k total citations · 4 hit papers
337 papers, 12.1k citations indexed

About

Koutaro Yokote is a scholar working on Molecular Biology, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Koutaro Yokote has authored 337 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Molecular Biology, 102 papers in Surgery and 92 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Koutaro Yokote's work include Lipoproteins and Cardiovascular Health (61 papers), Diabetes Treatment and Management (37 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (36 papers). Koutaro Yokote is often cited by papers focused on Lipoproteins and Cardiovascular Health (61 papers), Diabetes Treatment and Management (37 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (36 papers). Koutaro Yokote collaborates with scholars based in Japan, United States and Russia. Koutaro Yokote's co-authors include Seijiro Mori, Julio Rosenstock, Barbara McGowan, Robert F. Kushner, Rachel L. Batterham, Sean Wharton, John Wilding, Luc F. Van Gaal, Thomas A. Wadden and Ildiko Lingvay and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Koutaro Yokote

320 papers receiving 11.8k citations

Hit Papers

Once-Weekly Semaglutide i... 2010 2026 2015 2020 2021 2010 2022 2013 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.5k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →
  2. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species
    2010 531 citations Sawako Suzuki, Tomoaki Tanaka et al. profile →
  3. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 515 citations John Wilding, Rachel L. Batterham et al. profile →
  4. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan ^|^mdash;2012 Version
    2013 378 citations Tamio Teramoto, Junichi Sasaki et al. Journal of Atherosclerosis and Thrombosis profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Koutaro Yokote Japan 47 4.6k 3.6k 2.8k 1.8k 1.6k 337 12.1k
Francesco Giorgino Italy 59 4.3k 0.9× 5.2k 1.5× 2.5k 0.9× 2.7k 1.5× 914 0.6× 316 12.4k
Rafael Simó Spain 68 5.0k 1.1× 4.1k 1.1× 1.9k 0.7× 1.8k 1.0× 775 0.5× 418 17.5k
Gian Paolo Fadini Italy 65 6.5k 1.4× 4.4k 1.2× 2.8k 1.0× 1.9k 1.1× 706 0.5× 323 14.9k
Tsutomu Hirano Japan 47 2.0k 0.4× 3.8k 1.1× 3.0k 1.1× 1.9k 1.1× 787 0.5× 252 9.0k
Eelco J.P. de Koning Netherlands 52 3.9k 0.8× 2.7k 0.8× 3.9k 1.4× 1.3k 0.7× 439 0.3× 234 10.5k
Avraham Karasik Israel 41 4.0k 0.9× 5.5k 1.5× 2.2k 0.8× 1.5k 0.8× 867 0.6× 126 10.8k
Marta Ruiz‐Ortega Spain 70 6.9k 1.5× 2.2k 0.6× 2.0k 0.7× 1.6k 0.9× 1.0k 0.7× 265 18.2k
Atsunori Kashiwagi Japan 55 4.2k 0.9× 3.5k 1.0× 2.2k 0.8× 2.1k 1.2× 592 0.4× 231 11.3k
Matteo Pirro Italy 62 2.7k 0.6× 1.6k 0.4× 2.7k 1.0× 1.2k 0.7× 653 0.4× 263 11.2k
Michael Lehrke Germany 40 3.2k 0.7× 2.2k 0.6× 1.5k 0.5× 2.5k 1.4× 663 0.4× 132 9.1k

Countries citing papers authored by Koutaro Yokote

Since Specialization
Citations

This map shows the geographic impact of Koutaro Yokote's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koutaro Yokote with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koutaro Yokote more than expected).

Fields of papers citing papers by Koutaro Yokote

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koutaro Yokote. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koutaro Yokote. The network helps show where Koutaro Yokote may publish in the future.

Co-authorship network of co-authors of Koutaro Yokote

This figure shows the co-authorship network connecting the top 25 collaborators of Koutaro Yokote. A scholar is included among the top collaborators of Koutaro Yokote based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koutaro Yokote. Koutaro Yokote is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arai, Hidenori, Shizuya Yamashita, Eiichi Araki, et al.. (2025). Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study. Journal of Atherosclerosis and Thrombosis. 32(8). 1006–1026. 3 indexed citations
2.
Miyata, Masaaki, Masayuki Kuroda, Junko Miyoshi, et al.. (2024). Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype. Journal of clinical lipidology. 19(1). 125–133.
3.
Yamashita, Shizuya, Eiichi Araki, Hidenori Arai, et al.. (2024). Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia—A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study. Journal of Atherosclerosis and Thrombosis. 32(3). 367–384. 2 indexed citations
4.
Arai, Hidenori, Shizuya Yamashita, Eiichi Araki, et al.. (2024). Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial. Journal of Atherosclerosis and Thrombosis. 31(11). 1517–1538. 4 indexed citations
5.
Bolanos, Lyndsey, Kwangmin Choi, Shokichi Tsukamoto, et al.. (2024). Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 38(5). 1032–1045. 3 indexed citations
6.
Suzuki, Sawako, Divya Venkatesh, Hiroaki Kanda, et al.. (2022). GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma. Cancer Research. 82(18). 3209–3222. 108 indexed citations
7.
Kaneko, Hideo, Minoru Takemoto, Hiroaki Murakami, et al.. (2022). Rothmund‐Thomson syndrome investigated by two nationwide surveys in Japan. Pediatrics International. 64(1). e15120–e15120. 2 indexed citations
8.
Wilding, John, Rachel L. Batterham, Salvatore Calanna, et al.. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 384(11). 989–1002. 2476 indexed citations breakdown →
9.
Fujimoto, Hiroshi, Masayuki Kuroda, Yasuyuki Aoyagi, et al.. (2020). Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer. Breast Cancer Research and Treatment. 180(3). 625–634. 1 indexed citations
10.
Isshiki, Yusuke, Yaeko Nakajima‐Takagi, Motohiko Oshima, et al.. (2019). KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis. Blood Advances. 3(17). 2537–2549. 20 indexed citations
11.
Hattori, Akiko, Minoru Takemoto, Hirotake Tokuyama, Masaya Koshizaka, & Koutaro Yokote. (2017). Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 126. 138–143. 7 indexed citations
12.
Arai, Hidenori, Shun Ishibashi, Shizuya Yamashita, et al.. (2015). Abstract 13374: Efficacy and Safety of K-877, a Potent and Selective PPAR-α Modulator (SPPARMα), in Combination With Statins in Japanese Patients With Dyslipidemia. Circulation. 132(suppl_3). 6 indexed citations
13.
Yamashita, Shizuya, Shun Ishibashi, Hidenori Arai, et al.. (2013). Abstract 15652: Comparison of the Novel Peroxisome Proliferator-Activated Receptor Alpha Agonist K-877 and Fenofibrate on High-Density Lipoprotein Subclass Distribution Determined by High-Performance Liquid Chromatography in Patients With Dyslipidemia. Circulation. 128. 5 indexed citations
14.
Muto, Tomoya, Goro Sashida, Motohiko Oshima, et al.. (2013). Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. The Journal of Experimental Medicine. 210(12). 2627–2639. 137 indexed citations
15.
Yokote, Koutaro, Shun Ishibashi, Shizuya Yamashita, et al.. (2013). Abstract 17336: Marked Increase of Plasma Fibroblast Growth Factor 21 in Dyslipidemic Patients Treated With K-877, a Novel Highly Potent and Specific Peroxisome Proliferator-Activated Receptor Alpha Agonist. Circulation. 128. 2 indexed citations
16.
Tanaka, Asami, Kenichi Sakurai, Kentaro Kaneko, et al.. (2011). The Role of the Hypoxia-Inducible Factor 1 Binding Site in the Induction of Aquaporin-1 mRNA Expression by Hypoxia. DNA and Cell Biology. 30(8). 539–544. 21 indexed citations
17.
Teramoto, Tamio, Junichi Sasaki, Hirotsugu Ueshima, et al.. (2007). Risk Factors of Atherosclerotic Diseases - Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese. Journal of Atherosclerosis and Thrombosis. 14(6). 267–277. 46 indexed citations
18.
Kobayashi, Junji, Shunichi Murano, Koutaro Yokote, et al.. (2000). Marked decrease in plasma apolipoprotein A-I and high density lipoprotein-cholesterol in a case with Werner syndrome. Clinica Chimica Acta. 293(1-2). 63–73. 5 indexed citations
19.
Matsumoto, Tarô, Koutaro Yokote, Minoru Takemoto, et al.. (2000). Differential Interaction of CrkII Adaptor Protein with Platelet-Derived Growth Factor α- and β-Receptors Is Determined by Its Internal Tyrosine Phosphorylation. Biochemical and Biophysical Research Communications. 270(1). 28–33. 15 indexed citations
20.
Saito, Yuji, Yuji Saito, Seijiro Mori, et al.. (1996). Phosphatidylinositol 3-Kinase Activity Is Required for the Activation Process of Focal Adhesion Kinase by Platelet-Derived Growth Factor. Biochemical and Biophysical Research Communications. 224(1). 23–26. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Giorgino Breakdown of academic impact, for papers by Rafael Simó Breakdown of academic impact, for papers by Gian Paolo Fadini Breakdown of academic impact, for papers by Tsutomu Hirano Breakdown of academic impact, for papers by Eelco J.P. de Koning Breakdown of academic impact, for papers by Avraham Karasik Breakdown of academic impact, for papers by Marta Ruiz‐Ortega Breakdown of academic impact, for papers by Atsunori Kashiwagi Breakdown of academic impact, for papers by Matteo Pirro Breakdown of academic impact, for papers by Michael Lehrke
Rankless by CCL
2026